Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

3.185 +0.245 (+8.33%)
Streaming Delayed Price Updated: 11:39 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Recap: These 7 Artificial Intelligence (AI) Stock Categories Had Returns From +2 To +15% In February ↗
This article is a recap of how 7 artificial intelligence stock categories did in February, and YTD, compared to each other to help you make prudent investment decisions accordingly. 
Via Talk Markets
Topics Artificial Intelligence
News headline image
AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD ↗
Grand View Research says the global 
Via Talk Markets
News headline image
3 Highly Rated Biotech Stocks to Buy for 300% Gains ↗
Biotech stocks like those discussed here have the potential to produce 300% returns and benefit from high analyst ratings. 
Via InvestorPlace
News headline image
Recap: AbCellera Biologics Q4 Earnings ↗
 
Via Benzinga
News headline image
AbCellera Announces Resignation of Board Member
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera to Present at Upcoming Investor Conferences in March
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript ↗
ABCL earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
AbCellera Reports Full Year 2023 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Earnings Scheduled For February 20, 2024 ↗
Companies Reporting Before The Bell • Barclays (NYSE:BCS) is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion. 
Via Benzinga
News headline image
These 9 AI Stock Categories Performed From +18% To -4% Last Week ↗
A synopsis of the performances of each of the 9 different artificial intelligence stock categories last week, and YTD, along with a description of what makes up each category and the stocks included in... 
Via Talk Markets
Topics Artificial Intelligence
News headline image
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics ↗
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway. 
Via Talk Markets
Topics Artificial Intelligence
News headline image
AbCellera to Report Full Year 2023 Financial Results on February 20, 2024
From AbCellera Biologics Inc.
Via Business Wire
News headline image
4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond ↗
Healthcare stocks have underperformed in 2023, but that is expected to change this year. 
Via The Motley Fool
News headline image
3 Growth Stocks That Could Go Parabolic in 2024 ↗
These innovation-oriented companies could take flight this year. 
Via The Motley Fool
News headline image
AI-Focused Drug Discovery Stocks Index Up 26% In December ↗
With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds massive potential to increase the accessibility of drugs and to treat presently incurable conditions. 
Via Talk Markets
News headline image
AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AI-Focused Drug Discovery Stocks Index Up 10.6% Last Week ↗
A new study concludes that the AI method of drug discovery is up to 250 times more efficient than the traditional method. 
Via Talk Markets
Topics Artificial Intelligence
News headline image
AI Meets Biotech: 3 Top Stocks Transforming Medical Science ↗
The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology. 
Via InvestorPlace
Topics Artificial Intelligence
News headline image
The 10 Stocks Using AI To Develop New Drugs Were Up 4%, On Average, Last Week ↗
If, as Morgan Stanley postulates, a $50 billion AI drug discovery revolution is underway, here are 10 publicly-traded micro- and small-cap clinical stage pharma companies that are embracing AI to... 
Via Talk Markets
Topics Artificial Intelligence
News headline image
Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In November ↗
The AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions. 
Via Talk Markets
Topics Artificial Intelligence
News headline image
AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023
From AbCellera Biologics Inc.
Via Business Wire
News headline image
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
From AbCellera Biologics Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
AbCellera Biologics (ABCL) Q3 2023 Earnings Call Transcript ↗
ABCL earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
AbCellera Reports Q3 2023 Business Results
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
From AbCellera Biologics Inc.
Via Business Wire
News headline image
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
Multi-year collaboration to jointly discover, develop, and commercialize novel oncology medicines for up to five programs, with the first ADC program focusing on a SMARCA degrader 
From Prelude Therapeutics, Inc.; AbCellera
Via GlobeNewswire
News headline image
AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023
From AbCellera Biologics Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.